Proficio Capital Partners LLC Buys Shares of 25,583 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Proficio Capital Partners LLC purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 25,583 shares of the biotechnology company’s stock, valued at approximately $192,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $46,000. R Squared Ltd bought a new stake in BioCryst Pharmaceuticals during the 4th quarter worth about $48,000. KBC Group NV boosted its position in BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares during the last quarter. Quantinno Capital Management LP acquired a new position in BioCryst Pharmaceuticals during the 3rd quarter valued at about $82,000. Finally, SkyView Investment Advisors LLC raised its position in shares of BioCryst Pharmaceuticals by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BCRX shares. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price on the stock. Needham & Company LLC raised their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, Evercore ISI upped their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $7.83 on Friday. The firm has a 50 day moving average price of $8.17 and a two-hundred day moving average price of $7.82. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $9.50. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -12.84 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The company’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.28 EPS. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.